Tuesday, September 8, 2026 · Bullpen.News

Skip to this day’s stories

Bullpen.News From Edwin Dorsey

Get Daily Recap Feedback

ContextLogic Acquires gChem (LOGC): Update and Valuation

ContextLogic will acquire specialty-solvent maker gChem for $850 million, funded by a $650 million rights offering and $250 million of debt, expanding Abrams Capital’s acquisition platform.

Hidden Gems Investing Sep 8 5 clicks

Sep 6 TII $284M

Titan Mining Q2 Update

Sylence Capital 4 clicks

Sep 2 SMPL $852M

A Busted Businesses or a Cyclical Bottom?

The Value Road 12 clicks

From X

@leevalueroach Sep 8

Lee Roach on X

Once again an awful day to be a 200-IQ $BUR holder

@ACapitalLP Sep 8

A Capital on X

$VRRM *

@TimyanBankAlert Sep 8

Timyan Bank Alert on X

The Pipeline: Blue Ridge $BRBS worked to shore up its business between two sale offers | S&P Global Market Intelligence https://t.co/nfapDdBkkI

@majgeoinvesting Sep 8

Maj Soueidan on X

Well, add $PPIH to this sleep with “one eye open” earnings report list. Tomorrow: $OCC + $PPIH’s first ever earnings call. At least $RFIL is now confirmed and pushed to next week (September 14). https://t.co/R6wurrniCi

@Mike10947310 Sep 8

Mike on X

I am not saying $SIF deserves nearly the same multiple at all, but it is surprising to see a comp go for 26x EBITDA when it’s at like… single digits Caveat is SIF hasn’t been focusing on power space (though historically they did play in this space)

@DeepSailCapital Sep 8

Deep Sail Capital on X

$GPRO - That’s a wrap https://t.co/bmx1RdCCNe

@Mike10947310 Sep 8

Mike on X

@KairosPraxis Agreed but also fwiw… $SIF is at like 7x (!)

@stockgutter Sep 8

SG on X

Thought $SIEB might struggle a bit at the $2.50 level since that is around where the prior support from last November was (failed in February). However, shares punched through that level with little hesitation. Looks like more upside. I'm still long. https://t.co/qlCYr6P7tS https://t.co/uesZlSX7vr

Sangamo Bankruptcy (SGMOQ)

Sangamo Therapeutics’ Chapter 11 asset sales leave common equity tied to $100 million in PTC Fabry therapy approval milestones and a…

Triple S Special Situations Investing Sep 2 6 clicks

Hydreight Technologies: A Strong Quarter With Some Yellow Flags (Rating Downgrade)

Hydreight Technologies' Q2 revenue rose 12% sequentially to $28 million, while gross margin fell to 19.4% and cash burn stayed elevated,…

Fernanda Galvez Jalil Sep 2 1 click

An ATM that starts to spit out cash

Andrada Mining’s Uis ore sorter targets higher tin grades and lower unit costs after FY26 operating cash flow reached £4.7 million, but…

The Oak Bloke Sep 2 7 clicks

Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case

Tectonic Therapeutic's TX45 CpcPH-HFpEF program gains support from Merck's CADENCE data; Phase 1b hemodynamics and cash through Q1 2029 set…

Equity Eagle Sep 2 2 clicks

EVC Update

EVC reported a solid second quarter and outlook.

Nat Stewart - Stock Picking Newsletter Sep 1 15 clicks

$LMB: Limbach missed the data center boom. Is that the opportunity? | 1 Main Capital

Limbach's EBITDA fell 30% as organic revenue declined, but 1 Main Capital calls the weakness temporary and views CYMCOR as its first…

Yet Another Value Podcast Sep 1 9 clicks

IEH Corporation: Research Note

IEH Corporation won $6.5 million of APKWS orders, lifting backlog above $45 million as defense connector demand drives capacity expansion.

Atrium Research - Equity Research Sep 1 1 click

GoPro sold itself at 9:20 AM to get ahead of a meme stock

GoPro rushed out its Starman Optical merger after Markiplier-driven buying sent GPRO up roughly 90% premarket, offering shareholders $1.14…

Yet Another Value Blog Sep 1 4 clicks

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

Shattuck Labs pivots to DR3-targeted IBD therapy SL-325, funded through a Phase 2b readout as it competes with anti-TL1A drugs.

Equity Eagle Sep 1

Late August 2026 Random Ramblings

Higher rates could compress equity multiples and raise AI data center lease costs, while UWMC and Cogent raise questions about CEO-driven…

Yet Another Value Podcast Aug 27 13 clicks

CUE · short

Cue Biopharma

Cue Biopharma faces a deteriorating balance sheet, recurring operating losses, ATM dilution and PIPE-investor selling pressure.

Value Investors Club May 4 3 clicks

Publications we follow

Every publication on this site, hand-picked.

108 publications

YouTube 4

Blogs 12

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

72 accounts

Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.